ES2141750T3 - Composicion que contiene a la vez una forma soluble y una forma insoluble de un inmunogeno. - Google Patents

Composicion que contiene a la vez una forma soluble y una forma insoluble de un inmunogeno.

Info

Publication number
ES2141750T3
ES2141750T3 ES93307185T ES93307185T ES2141750T3 ES 2141750 T3 ES2141750 T3 ES 2141750T3 ES 93307185 T ES93307185 T ES 93307185T ES 93307185 T ES93307185 T ES 93307185T ES 2141750 T3 ES2141750 T3 ES 2141750T3
Authority
ES
Spain
Prior art keywords
immunogen
composition containing
same time
forms
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93307185T
Other languages
English (en)
Other versions
ES2141750T5 (es
Inventor
Robert S Becker
Karen Biscardi
Laura Ferguson
Lorne Erdile
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Sanofi Pasteur Inc
Original Assignee
Connaught Laboratories Ltd
Connaught Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25479200&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2141750(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Connaught Laboratories Ltd, Connaught Laboratories Inc filed Critical Connaught Laboratories Ltd
Application granted granted Critical
Publication of ES2141750T3 publication Critical patent/ES2141750T3/es
Publication of ES2141750T5 publication Critical patent/ES2141750T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Jib Cranes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PRESENTA UN INMUNOGENO PARA INDUCIR UNA RESPUESTA INMUNE A ANTIGENOS, PARTICULARMENTE ANTIGENOS VIRALES DEBILMENTE INMUNOGENICOS, TALES COMO EL ANTIGENO DE LA HEMAGLUTININA (HA) A PARTIR DEL VIRUS DE LA INFLUENZA QUE CONTIENE EL ANTIGENO EN DOS FORMAS FISIOQUIMICAS, DIFERENTES. EL INMUNOGENO PUEDE COMPRENDER UNA COMPOSICION QUE CONTENGA LAS DOS FORMAS DE ANTIGENO O PUEDE HABER DOS COMPOSICIONES QUE CONTENGAN LAS FORMAS DE ANTIGENO RESPECTIVAS. LA ADMINISTRACION DEL INMUNOGENO A UN ANIMAL EN UNO O MAS LUGARES DA UNA RESPUESTA INMUNE MEJORADA EN COMPARACION CON EL INMUNOGENO QUE COMPRENDE SOLAMENTE UNA DE LAS DOS FORMAS DE ANTIGENOS.
ES93307185T 1992-09-14 1993-09-13 Composicion que contiene a la vez una forma soluble y una forma insoluble de un inmunogeno. Expired - Lifetime ES2141750T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94317392A 1992-09-14 1992-09-14
US943173 1992-09-14

Publications (2)

Publication Number Publication Date
ES2141750T3 true ES2141750T3 (es) 2000-04-01
ES2141750T5 ES2141750T5 (es) 2005-12-01

Family

ID=25479200

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93307185T Expired - Lifetime ES2141750T5 (es) 1992-09-14 1993-09-13 Composicion que contiene a la vez una forma soluble y una forma insoluble de un inmunogeno.

Country Status (15)

Country Link
US (4) US5662909A (es)
EP (1) EP0588578B2 (es)
JP (1) JP2512689B2 (es)
AT (1) ATE187338T1 (es)
AU (1) AU677592B2 (es)
CA (1) CA2105629A1 (es)
DE (1) DE69327214T3 (es)
DK (1) DK0588578T4 (es)
ES (1) ES2141750T5 (es)
FI (1) FI110234B (es)
GR (1) GR3032543T3 (es)
IL (2) IL106968A (es)
NO (1) NO313178B1 (es)
PT (1) PT588578E (es)
ZA (1) ZA936629B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US6251405B1 (en) * 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
AU2596600A (en) 1998-12-31 2000-07-31 Chiron Corporation Modified hiv env polypeptides
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1980617A1 (en) * 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
US20050106137A1 (en) * 2000-05-05 2005-05-19 Stephen Grimes Chimeric peptide immunogens
US6660249B2 (en) * 2000-12-27 2003-12-09 Salus Pharma, Inc. Inhalable dry powder aztreonam for treatment and prevention of pulmonary bacterial infections
US20030198621A1 (en) * 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
EP1427806A4 (en) * 2001-08-31 2006-04-26 Chiron Corp ANTIGENIC HIV-TYPE B POLYPEPTIDE-CODING POLYNUCLEOTIDES, POLYPEPTIDES, AND USES THEREOF
US7211258B2 (en) * 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use
US7425331B2 (en) * 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
US6814729B2 (en) 2002-06-27 2004-11-09 Technovision Gmbh Laser vision correction apparatus and control method
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
GB8610983D0 (en) * 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
US4946676A (en) * 1986-08-27 1990-08-07 De Staat Der Nederlanden Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic, sequentially homologous peptide
EP0270295A3 (en) * 1986-12-03 1989-08-02 Connaught Laboratories Limited Conjugate vaccine
DK425789A (da) * 1988-08-31 1990-03-01 Smithkline Beecham Corp Vaccinale polypeptider
JPH0678245B2 (ja) * 1989-07-04 1994-10-05 東興薬品工業株式会社 鼻腔内噴霧投与用インフルエンザワクチンゲル製剤
EP0536335A4 (en) * 1990-06-15 1993-07-14 Yale University Compositions and methods for the prevention and diagnosis of lyme disease
WO1993008299A1 (en) * 1991-10-18 1993-04-29 Connaught Laboratories Inc. Preparation of recombinant borrelia proteins

Also Published As

Publication number Publication date
FI110234B (fi) 2002-12-31
AU677592B2 (en) 1997-05-01
ES2141750T5 (es) 2005-12-01
FI934013A0 (fi) 1993-09-14
EP0588578B1 (en) 1999-12-08
IL130075A0 (en) 2000-02-29
GR3032543T3 (en) 2000-05-31
EP0588578B2 (en) 2005-04-13
US5662909A (en) 1997-09-02
JP2512689B2 (ja) 1996-07-03
DE69327214D1 (de) 2000-01-13
US6024963A (en) 2000-02-15
PT588578E (pt) 2000-05-31
ATE187338T1 (de) 1999-12-15
US5853736A (en) 1998-12-29
CA2105629A1 (en) 1994-03-15
AU4622693A (en) 1994-03-24
US5837264A (en) 1998-11-17
IL106968A (en) 1999-10-28
EP0588578A1 (en) 1994-03-23
DK0588578T4 (da) 2005-07-25
JPH06192125A (ja) 1994-07-12
NO933261L (no) 1994-03-15
ZA936629B (en) 1994-03-30
DK0588578T3 (da) 2000-03-27
IL106968A0 (en) 1993-12-28
DE69327214T2 (de) 2000-09-07
DE69327214T3 (de) 2005-12-01
NO313178B1 (no) 2002-08-26
FI934013L (fi) 1994-03-15
NO933261D0 (no) 1993-09-13

Similar Documents

Publication Publication Date Title
AR065970A2 (es) Una composicion farmaceutica oral solida que comprende una combinacion de metformin y glibenclamida y uso de dicha composicion
ES2104556T3 (es) Peptidos que tienen propiedades inmunologicas de hiv-2.
FI934013A0 (fi) Foerstaerkning av immunreaktion
ATE108334T1 (de) Immunotherapeutisches zubereitungen für die behandlung von aids.
FI20001231A7 (fi) 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
ES2182107T3 (es) Uso en una composicion de un extracto de al menos una labiada del genero rosmarinarus, cultivado in vitro.
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
ES488168A0 (es) Proceso para la preparacion de tabletas farmaceuticas o medicinales de administracion oral, con liberacion retardada delagente activo, en tabletas en las que la cantidad de libera-cion del agente activo es predeterminada.
HRP20020787B1 (hr) Postupak liječenja upotrebom kompleksa ligand-imunogen
AR026059A1 (es) Virus de plantas modificadas y metodos para su uso
ES2103828T3 (es) Particulas viricas ensambladas y su uso en una vacuna contra una enfermedad rotavirica.
TR200102024T2 (tr) Yeni tedavi.
ES2036526T3 (es) Composiciones de interferon.
NO890565L (no) Forhindring og behandling av retroviral sykdom.
ES2082201T3 (es) Uso de il-4 para mejorar la respuesta inmune a las pruebas de antigenos infecciosos.
NL7805501A (nl) Nieuw vaccin ten gebruike bij de immunotherapie van neoplasmische ziekten.
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
ATE205397T1 (de) Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
AR027738A1 (es) Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas
BR0211181A (pt) Formulação vacinal
BE601851A (fr) Vaccin antipoliomyélitique et sa préparation
USD146325S (en) Design for a sandal
ES347271A1 (es) Procedimiento para preparar benzodiazapinas.
EA202190269A1 (ru) Фармацевтическая композиция в виде жевательной таблетки диосмина или флавоноидной фракции
GR33412B (el) Μεθοδος παρασκευης φαρμακευτικων συνθεσεων δια την θεραπειαν τησαθηροσκληρωσεως, αρτηριοσκληρυνσεωσκαι συγγενων μεταβολικων ασθενειων.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 588578

Country of ref document: ES